Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway

Cell Research

Volumn 25, Issue 7, 2015, Pages 801-817

  Li, Youjun ^a   Zhou, Hao ^c   Li, Fengzhi ^c   Chan, Siew Wee ^d   Lin, Zhijie ^a   Wei, Zhiyi ^a,e   Yang, Zhou ^a   Guo, Fusheng ^d   Lim, Chun Jye ^d   Xing, Wancai ^c   Shen, Yuequan ^c   Hong, Wanjin ^d   Long, Jiafu ^c   Zhang, Mingjie ^a,b  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c NANKAI UNIVERSITY   (China)

^d INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^e SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiomotin; Hippo pathway; Lats1 2; Merlin; Nf2; PAK1 2; Phosphorylation

Indexed keywords

AMOT PROTEIN, HUMAN; CARRIER PROTEIN; HIPPO PROTEIN, HUMAN; LATS1 PROTEIN, HUMAN; MEMBRANE PROTEIN; MERLIN; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

CELL PROLIFERATION; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CARRIER PROTEINS; CELL PROLIFERATION; GENES, TUMOR SUPPRESSOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; NEUROFIBROMIN 2; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 84942987892     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2015.69     Document Type: Article

References (62)

1. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363:515-521.
2. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis tumor suppressor. Cell 1993; 72:791-800.
3. Bianchi AB, Hara T, Ramesh V, et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat Genet 1994; 6:185-192.
4. Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett 2014; 588:2743-2752.
5. Schroeder RD, Angelo LS, Kurzrock R. NF2/merlin in hereditary neurofibromatosis 2 versus cancer: biologic mechanisms and clinical associations. Oncotarget 2014; 5:67-77.
6. Petrilli AM, Fernandez-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene 2015 Apr 20. doi: 10. 1038/ onc. 2015. 125
7. Fehon RG, McClatchey AI, Bretscher A. Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010; 11:276-287.
8. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19:491-505.
9. Yu FX, Guan KL. The Hippo pathway: regulators and regulations. Genes Dev 2013; 27:355-371.
10. Hamaratoglu F, Willecke M, Kango-Singh M, et al. The tumour-suppressor genes NF2/Merlin and expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006; 8:27-36.
11. Harvey K, Tapon N. The Salvador-Warts-Hippo pathway-an emerging tumour-suppressor network. Nat Rev Cancer 2007; 7:182-191.
12. Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development 2011; 138:9-22.
13. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013; 154:1342-1355.
14. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005; 122:421-434.
15. Pan D. Hippo signaling in organ size control. Genes Dev 2007; 21:886-897.
16. Li W, You L, Cooper J, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010; 140:477-490.
17. Pearson MA, Reczek D, Bretscher A, Karplus PA. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 2000; 101:259-270.
18. Li Q, Nance MR, Kulikauskas R, et al. Self-masking in an intact ERM-merlin protein: An active role for the central alpha-helical domain. J Mol Biol 2007; 365:1446-1459.
19. Gonzalez-Agosti C, Wiederhold T, Herndon ME, Gusella J, Ramesh V. Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF. J Biol Chem 1999; 274:34438-34442.
20. Sher I, Hanemann CO, Karplus PA, Bretscher A. The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state. Dev Cell 2012; 22:703-705.
21. Shaw RJ, Paez JG, Curto M, et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell 2001; 1:63-72.
22. Xiao GH, Beeser A, Chernoff J, Testa JR. p21-activated kinase links Rac/Cdc42 signaling to merlin. J Biol Chem 2002; 277:883-886.
23. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 2003; 12:841-849.
24. Surace EI, Haipek CA, Gutmann DH. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene 2004; 23:580-587.
25. Rong R, Surace EI, Haipek CA, Gutmann DH, Ye K. Serine 518 phosphorylation modulates merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 2004; 23:8447-8454.
26. Kissil JL, Johnson KC, Eckman MS, Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J Biol Chem 2002; 277:10394-10399.
27. Ali Khajeh J, Ju JH, Atchiba M, et al. Molecular conformation of the full-length tumor suppressor NF2/Merlin - A smallangle neutron scattering study. J Mol Biol 2014; 426:2755-2768.
28. Lallemand D, Curto M, Saotome I, Giovannini M, Mc-Clatchey AI. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev 2003; 17:1090-1100.
29. Gladden AB, Hebert AM, Schneeberger EE, McClatchey AI. The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev Cell 2010; 19:727-739.
30. Yi C, Troutman S, Fera D, et al. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011; 19:527-540.
31. McLaughlin ME, Kruger GM, Slocum KL, et al. The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion. Proc Natl Acad Sci USA 2007; 104:3261-3266.
32. Hirate Y, Hirahara S, Inoue K, et al. Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos. Curr Biol 2013; 23:1181-1194.
33. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/ Merlin. J Cell Biol 2007; 177:893-903.
34. Benhamouche S, Curto M, Saotome I, et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 2010; 24:1718-1730.
35. Moleirinho S, Guerrant W, Kissil JL. The Angiomotins-from discovery to function. FEBS Lett 2014; 588:2693-2703.
36. Nguyen R, Reczek D, Bretscher A. Hierarchy of merlin and ezrin N-and C-terminal domain interactions in homo-and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J Biol Chem 2001; 276:7621-7629.
37. Bretscher A, Edwards K, Fehon RG. ERM proteins and merlin: integrators at the cell cortex. Nat Rev Mol Cell Biol 2002; 3:586-599.
38. Reczek D, Bretscher A. The carboxyl-terminal region of EBP50 binds to a site in the amino-terminal domain of ezrin that is masked in the dormant molecule. J Biol Chem 1998; 273:18452-18458.
39. Ahronowitz I, Xin W, Kiely R, Sims K, MacCollin M, Nunes FP. Mutational spectrum of the NF2 gene: A meta-analysis of years of research and diagnostic laboratory findings. Hum Mutat 2007; 28:1-12.
40. Shimizu T, Seto A, Maita N, et al. Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Biol Chem 2002; 277:10332-10336.
41. LaJeunesse DR, McCartney BM, Fehon RG. Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J Cell Biol 1998; 141:1589-1599.
42. Zhao B, Li L, Lu Q, et al. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 2011; 25:51-63.
43. Aragona M, Panciera T, Manfrin A, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 2013; 154:1047-1059.
44. Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. Nature 2011; 474:179-183.
45. Wada K, Itoga K, Okano T, Yonemura S, Sasaki H. Hippo pathway regulation by cell morphology and stress fibers. Development 2011; 138:3907-3914.
46. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 2012; 26:54-68.
47. Sansores-Garcia L, Bossuyt W, Wada K, et al. Modulating F-actin organization induces organ growth by affecting the Hippo pathway. EMBO J 2011; 30:2325-2335.
48. Mana-Capelli S, Paramasivam M, Dutta S, McCollum D. Angiomotins link F-actin architecture to Hippo pathway signaling. Mol Biol Cell 2014; 25:1676-1685.
49. Leung CY, Zernicka-Goetz M. Angiomotin prevents pluripotent lineage differentiation in mouse embryos via Hippo pathway-dependent and-independent mechanisms. Nat Commun 2013; 4:2251.
50. Chan SW, Lim CJ, Guo F, Tan I, Leung T, Hong W. Actin-binding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation. J Biol Chem 2013; 288:37296-37307.
51. Adler JJ, Johnson DE, Heller BL, et al. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci USA 2013; 110:17368-17373.
52. Dai X, She P, Chi F, et al. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem 2013; 288:34041-34051.
53. Yu J, Zheng Y, Dong J, Klusza S, Deng WM, Pan D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell 2010; 18:288-299.
54. Paramasivam M, Sarkeshik A, Yates JR III, Fernandes MJ, McCollum D. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor. Mol Biol Cell 2011; 22:3725-3733.
55. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W. Hippo pathway-independent restriction of TAZ and YAP by angiomotin. J Biol Chem 2011; 286:7018-7026.
56. Schuck P. Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J 2000; 78:1606-1619.
57. Schuck P. On the analysis of protein self-association by sedimentation velocity analytical ultracentrifugation. Anal Biochem 2003; 320:104-124.
58. Otwinowski Z, Minor W. Processing of X-ray diffraction data. Methods Enzymol 1997; 276:307-326.
59. Adams PD, Grosse-Kunstleve RW, Hung LW, et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 2002; 58:1948-1954.
60. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126-2132.
61. Davis IW, Leaver-Fay A, Chen VB, et al. MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 2007; 35:W375-W383.
62. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-4680.